BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Boca Pharmacal, Inc. Receives FDA Approval on Glycopyrrolate Tablets


10/24/2011 10:35:11 AM

CORAL SPRINGS, Fla., Oct. 21, 2011 /PRNewswire/ -- Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 mg and 2 mg, the generic version of Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, distributed by Shionogi Pharma, Inc. Glycopyrrolate tablets are intended for use as adjunctive therapy in the treatment of peptic ulcers.

"We're up to our third approval this year," said Robert Edwards, CEO of Boca Pharmacal. "Each approval including Glycopyrrolate Tablets has been consistent with our mission to pursue and provide products to the marketplace that are important to our customers, but may be overlooked by some of the huge multinationals. We're continuing to file new ANDAs, and will keep doing so in our ongoing effort to provide the generic products our customers and their patients need."

Boca Pharmacal, Inc.

Since its beginnings in 1998, Boca Pharmacal's mission has been to offer niche items that were overlooked by some of the larger generic companies as affordable alternatives to brand-named products.

Using multiple facilities across the globe, Boca Pharmacal has a broad reach and a reliable vertical structure that allows them to develop products that include tablets and capsules, semi-solids, solutions, and suspensions. They continue to invest in research and development to make sure they're providing their clients with a wide variety of offerings. The Boca Pharmacal product line is marketed to chains, wholesalers, distributors, managed markets and government agencies. Boca Pharmacal is located at 3550 NW 126th Avenue, Coral Springs, Florida, 33065. For more information visit www.bocapharmacal.com.

CONTACT:

Jennifer Moura


Boca Pharmacal


3550 NW 126th Ave


Coral Springs, FL 33065


Phone: (954) 346-8810


Email: info@bocapharmacal.com



SOURCE Boca Pharmacal, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES